Replay available

Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call

Castle Biosciences, Inc. (NASDAQ: CSTL) Q4 2025 earnings conference call, held 2026-02-26. Replay captured from the company's public earnings webcast.

Thu, February 26, 2026 at 4:30 PMendedReplay
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Camilla Sequeira

Vice President, Investor Relations and Corporate Affairs

Derek Matfield

Founder, President, and Chief Executive Officer

Frank Stokes

Chief Financial Officer

Matthew Parisi

Analyst, KeyBank Capital Markets

Mason Carrico

Analyst, Stephens

Replay transcript excerpt

Good afternoon and welcome to Castle Biosciences' fourth quarter and full year 2025 conference call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question and answer session. I would like to turn the call over to Camilla Sequeira, Vice President, Investor Relations and Corporate Affairs. Thank you, Operator. Good afternoon, everyone. Welcome to Castle Bioscience's fourth quarter and full year 2025 results conference call. Joining me today are Castle's founder, president, and chief executive officer, Derek Matfield, and chief financial officer, Frank Stokes. Information recorded on this call speaks only as of today, February 26, 2026. Therefore, if you are listening to the replay or reading the transcript of this call, any time sensitive information may no longer be accurate. A recording of today's call will be available on the investor relations page of the company's website for approximately three weeks following the conclusion of the call. Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements, including statements about expected addressable markets, statements containing projections regarding future events or our future financial or operational results and performance, including our anticipated 2026 total revenue and the impact of our investments and growth initiatives, including our ability to achieve long-term growth and drive stockholder value. Forward-looking statements are based upon current expectations and involve inherent risks and uncertainties, and there can be no assurances that the results contemplated in these statements will be realized. A number of factors and risks could cause actual results to diffe...

More from Castle Biosciences, Inc.